News | August 18, 2009

CMS May Cover FDG-PET for Cervical Cancer Staging, Not Diagnosis

August 18, 2009 - The Centers for Medicare and Medicaid Services (CMS) recently announced a proposed decision to cover FDG-PET for initial staging of cervical cancer, but to exclude coverage for diagnosis of the disease.

The American College of Radiology (ACR) noted that this proposed decision is consistent with request made by the ACR and the Society of Nuclear Medicine in a joint letter sent to CMS in July 2009.

ACR believes that this coverage proposal is in the best interest of the PET community, and asked CMS to reconsider Section 220.6 of the National Coverage Determinations Manual to end the prospective data collection requirements for FDG-PET for initial staging of cervical cancer.

CMS proposes that the evidence is adequate to determine that the results of FDG-PET imaging for cervical cancer staging of beneficiaries diagnosed with cervical cancer are used by the treating physician to make meaningful changes in therapeutic management and improve health outcomes, and thus are reasonable and necessary.

Therefore, CMS proposes to cover only one FDG PET for staging in beneficiaries who have biopsy proven cervical cancer when the beneficiary’s treating physician determines that the FDG PET study is needed to determine the location and/or extent of the tumor for the following therapeutic purposes related to the initial treatment strategy:

- To determine whether or not the beneficiary is an appropriate candidate for an invasive diagnostic or therapeutic procedure; or
- To determine the optimal anatomic location for an invasive procedure; or
- To determine the anatomic extent of tumor when the recommended anti-tumor treatment reasonably depends on the extent of the tumor.

The ACR, SNM, and others also noted that "CMS may find it appropriate to exclude coverage for diagnosis of cervical cancer since this disorder is initially diagnosed by biopsy." CMS reportedly agrees and proposes that there is no credible evidence that the results of FDG-PET imaging are useful to make the initial diagnosis of cervical cancer.

CMS is soliciting public comments on this proposed decision pursuant to §1862(l) of the Social Security Act. The public comment period is open until Sept. 14, 2009.

For more information:

Related Content

NIH Study of Brain Energy Patterns Provides New Insights into Alcohol Effects

NIH scientists present a new method for combining measures of brain activity (left) and glucose consumption (right) to study regional specialization and to better understand the effects of alcohol on the human brain. Image courtesy of Ehsan Shokri-Kojori, Ph.D., of NIAAA.

News | Neuro Imaging | March 22, 2019
March 22, 2019 — Assessing the patterns of energy use and neuronal activity simultaneously in the human brain improve
PET Scans Show Biomarkers Could Spare Some Breast Cancer Patients from Chemotherapy
News | PET Imaging | March 18, 2019
A new study positron emission tomography (PET) scans has identified a biomarker that may accurately predict which...
Researchers Create New Method for Developing Cancer Imaging Isotopes

Prototype fluidic system for zirconium-89 purification. Image taken through a hot cell window at the Department of Radiology, University of Washington. Image courtesy of Matthew O’Hara, Pacific Northwest National Laboratory

News | Radiopharmaceuticals and Tracers | March 14, 2019
A team of researchers at the University of Washington announced they developed a new automated system for producing...
Siemens Healthineers Announces First U.S. Install of Biograph Vision PET/CT
News | PET-CT | March 06, 2019
Siemens Healthineers’ new Biograph Vision positron emission tomography/computed tomography (PET/CT) system has been...
News | PET-CT | February 06, 2019
Technological advancements in positron emission tomography/computed tomography (PET/CT) offer both clinicians and pat
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
FDA Clears United Imaging Healthcare uExplorer Total-Body Scanner
Technology | PET-CT | January 23, 2019
January 23, 2019 — United Imaging Healthcare (United Imaging) announced U.S.
Subtle Medical Receives FDA Clearance, CE Mark for SubtlePET
Technology | PET Imaging | December 05, 2018
Subtle Medical announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SubtlePET. Subtle...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...